Capitalising Notch Biomarkers in the Drug Developm.. (CAPNOTCH)
Capitalising Notch Biomarkers in the Drug Development Market
Start date: Sep 1, 2013,
End date: Aug 31, 2014
"CapNotch is the translation from discovery of multimodal cancer biomarkers of the Notch pathway to a strong market proposition. Biomarker products for validating specificity, efficacy and toxicity of preclinical compounds that target this pathway are highly wanted by academia and industry and could fuel progress in this area. One step further lays the opportunity to exploit such biomarkers for patient stratification and treatment monitoring, as well for advancing clinical trials as for supporting clinical decision making. The outcome of CapNotch should guide the selection of the most feasible proposition."
Get Access to the 1st Network for European Cooperation